Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 7/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.33 |
| ▸ | HTR2A | P28223 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13040113 | 0.92 | NPY1R (0.36) | ADRB2ADRB1PSMB5CYP2D6HTR2A | |
| SCHEMBL14571130 | 0.89 | PSMB5 (0.37) | ADRB2ADRB1PSMB5CYP2D6 | |
| SCHEMBL13077519 | 0.87 | ADRB2 (0.43) | ADRB2ADRB1PSMB5CYP2D6HTR2A | |
| SCHEMBL13040066 | 0.86 | ADRB2 (0.43) | ADRB2ADRB1CYP2D6HTR2A | |
| SCHEMBL13040058 | 0.85 | ADRB2 (0.41) | ADRB2ADRB1PSMB5 | |
| SCHEMBL13040065 | 0.84 | ADRB1 (0.56) | ADRB2ADRB1CYP2D6 | |
| SCHEMBL13040082 | 0.81 | ADRB2 (0.51) | ADRB2ADRB1PSMB5 | |
| SCHEMBL13040109 | 0.79 | NPY1R (0.37) | ADRB2ADRB1CYP2D6HTR2A | |
| SCHEMBL13077486 | 0.78 | NPY1R (0.38) | ADRB2ADRB1PSMB5CYP2D6HTR2A | |
| SCHEMBL14571134 | 0.78 | ADRB2 (0.43) | ADRB2ADRB1CYP2D6HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825263-B2 | Nitrooxyderivatives of carvedilol and other beta blockers as antihypertensive | NICOX S.A. (FR) | 2010-11-02 | — | — | US | disclosed |
| US-20070072854-A1 | Nitrooxyderivatives of carvedilol and other beta blockers as antihypertensive | NICOX S.A. (FR) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072854-A1 | Nitrooxyderivatives of carvedilol and other beta blockers as antihypertensive | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885ADRB1 2/4885PSMB5 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.